Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29695408 | 1.00 | NOS1 (0.52) | NOS1DHFRCA1CA2 | |
| SCHEMBL64019 | 0.98 | NOS1 (0.54) | NOS1DHFRCA1CA2 | |
| SCHEMBL30311333 | 0.98 | NOS1 (0.54) | NOS1DHFRCA1CA2 | |
| Hydrochloric Acid SCHEMBL29568011 | 0.97 | NOS1 (0.52) | NOS1DHFRCA1CA2 | |
| Hydrochloric Acid SCHEMBL3101407 | 0.97 | NOS1 (0.52) | NOS1DHFRCA1CA2 | |
| Bromide SCHEMBL28586331 | 0.95 | NOS1 (0.51) | NOS1DHFRCA1CA2 | |
| Bromide SCHEMBL11634826 | 0.86 | DHFR (0.50) | DHFR | |
| SCHEMBL31087253 | 0.84 | PIK3CG (0.50) | NOS1CA1CA2 | |
| SCHEMBL11327528 | 0.84 | PIK3CG (0.50) | NOS1CA1CA2 | |
| Bromide SCHEMBL1116048 | 0.83 | NOS1 (0.52) | NOS1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5910588-A | REACTING SAID CRYSTAL MODIFICATION WITH TRIPHENYLPHOSPHINE DIBROMIDE, REACTING PRODUCT WITH DIETHYL 4-(N-METHYLAMINO)BENZOYL GLUTAMATE TO FORM DIETHYL METHOTREXATE, HYDROLYZING TO METHOTREXATE | HEINRICH MACK NACHF (DE) | 1999-06-08 | — | — | US | claimed |
| US-5760229-A | ADDING HYDROBROMIC ACID OR SALT TO AQUEOUS SOLUTION, HEATING | HEINRIC MACK NACHF (DE) | 1998-06-02 | — | — | US | claimed |
| US-4080325-A | REACTING TETRAAMINOPYRIMIDINE HYDROCHLORIDE WITH DIHYDROXYACETONE, MULTISTAGE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE | 1978-03-21 | — | — | US | claimed |
| US-4079056-A | REACTING 2,4-DIAMINO-6-PTERIDINE-METHANOL-HBR WITH TRIPHENYLPHOSPHINE DIBROMIDE OR PHOSPHORUS TRIBROMIDE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1978-03-14 | — | — | US | claimed |
| CN-114624382-A | Method for measuring content of 2, 4-diamino-6-halogenated methyl pteridine and salt thereof | 南京海润医药有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-112851676-A | Synthesis process of methotrexate | 贵州医科大学 | 2021-05-28 | — | — | CN | disclosed |
| US-9867828-B2 | Aminopterin dosage forms | AMINOPTERIN LLC (US) | 2018-01-16 | — | — | US | disclosed |
| EP-1855682-B1 | AMINOPTERIN DOSAGE FORMS FOR INFLAMMATORY DISORDERS | AMINOPTERIN LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170128452-A1 | Aminopterin Dosage Forms | AMINOPTERIN LLC (US) | 2017-05-11 | — | — | US | disclosed |
| EP-1778237-B1 | Use of Aminopterin for treating acute lymphoblastic leukemia | AMINOPTERIN LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-2039683-B1 | Vasculostatic agents and methods of use thereof | TARGEGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120128703-A1 | Aminopterin Dosage Forms and Methods for Inflammatory Disorders | KAMEN BARTON A (US) | 2012-05-24 | — | — | US | disclosed |
| EP-0154173-B1 | PTERIDINE DERIVATIVES, AN ANTICANCER COMPOSITION CONTAINING SAME AND A PROCESS FOR THE PRODUCTION OF SAID DERIVATIVES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-01-08 | — | — | EP | disclosed |
| US-4820706-A | Pteridine derivatives and method of treating leukemia employing same | RESEARCH CORPORATION (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0154173-A2 | Pteridine derivatives, an anticancer composition containing same and a process for the production of said derivatives | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1985-09-11 | — | — | EP | disclosed |
| US-4421913-A | SOLVENT EXTRACTION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1983-12-20 | — | — | US | disclosed |
| US-4080325-A | REACTING TETRAAMINOPYRIMIDINE HYDROCHLORIDE WITH DIHYDROXYACETONE, MULTISTAGE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE | 1978-03-21 | — | — | US | disclosed |
| US-4079056-A | REACTING 2,4-DIAMINO-6-PTERIDINE-METHANOL-HBR WITH TRIPHENYLPHOSPHINE DIBROMIDE OR PHOSPHORUS TRIBROMIDE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1978-03-14 | — | — | US | disclosed |
| US-4077957-A | INTERMEDIATE FOR METHOTREXATE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1978-03-07 | — | — | US | disclosed |
| US-4077957-A | INTERMEDIATE FOR METHOTREXATE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128452-A1 | Aminopterin Dosage Forms | AADAT, TPMT, ANPEP | NOS1 283/4885DHFR 795/4885CA1 1789/4885 |
| US-20120128703-A1 | Aminopterin Dosage Forms and Methods for Inflammatory Disorders | AADAT, TPMT, RNPEP | NOS1 194/4885DHFR 419/4885CA1 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.